Project Grant R61MH137105
Award Date
6/1/25
Completion Date
5/31/27
Dollars Obligated
$1.7M
Federal Agency
National Institute of Mental Health
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), is funding a $794,696 research study to investigate the pathophysiological mechanisms of cannabidiol (CBD) in stress regulation. The study will examine the impact of acute CBD administration on neural reactivity, limbic system function, neuronal viability, and endocrine/behavioral responses in a high-risk population of young adults with early life...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $541,080 Project Grant to The Trustees of Columbia University in the City of New York, Health Sciences Division, to conduct a human laboratory study on the effects of repeated cannabidiol (CBD) administration on cannabis abuse-liability and analgesia. The study aims to evaluate whether daily oral CBD administration alters the abuse-related and reinforcing effects of smoked...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program provides $1,050,000 to West Virginia University to conduct a 5-year study on the effects of cannabidiol (CBD) on the driving performance and cognitive function of healthy adults aged 18-30. The study aims to determine the dose-dependent effects of CBD on driving ability, drowsiness, sedation, and cognitive function, as well as any...
This Project Grant award for $760,143.00 was provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). The grant supports research to investigate the interaction between endocannabinoid and cholinergic signaling in the hippocampus and its impact on working memory and motivated reward seeking behavior. The research will utilize animal models and human subjects to study how CB1 receptor modulation of acetylcholine-dependent neuronal...
This $1,980,270 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a study to assess the neurobehavioral impacts of medical cannabis use in adults aged 35-65 who have chronic pain. The overarching aim is to evaluate cognition, neural function, and substance use disorder risk in a sample of 120 medical cannabis patients compared to 60 non-cannabis using controls. The study will measure behavioral...
This $376,078 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support an experimental study to explore the antecedents and consequences of cannabis use for coping purposes. The 5-year study will examine whether cannabis use increases after stress induction among individuals who use cannabis to cope, as well as the potential moderating roles of social anxiety and inhibitory control. It will also...
This federal Project Grant award, with the ID R21DA060486, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $268,470 grant will fund a 2-year study to investigate the impacts of policies around cannabidiol (CBD) on substance use behaviors, including opioid and alcohol use, as well as related overdose outcomes. The research team at the RAND Corporation will collect data on CBD dispensary locations and demographics to...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $189,540 to the University of Pittsburgh to conduct a 5-year research study on the effects of schizophrenia and cannabis use on cannabinoid CB1 receptor expression and signaling in the dorsolateral prefrontal cortex. The study aims to characterize the independent and combined impacts of schizophrenia and THC exposure on terminal type-specific CB1...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $1,912,273 to support the development of novel small-molecule inhibitors of the Sterol Carrier Protein-2 (SCP-2) as potential anxiolytic (anti-anxiety) therapeutics. The primary awardee, the Medical College of Wisconsin, Inc., will utilize computer-assisted drug design to develop and test these SCP-2 inhibitors, which are hypothesized to enhance...
This $245,625 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) supports the development of a preclinical therapeutic platform to create GABAA alpha5 receptor positive allosteric modulators (PAMs) for improving cognitive function in schizophrenia. The research aims to remediate excitatory/inhibitory imbalances in the hippocampus that contribute to cognitive dysfunction in neuropsychiatric disorders. The...